Pfizer Inks $500M+ Deal With Enodia to Develop Sec61-Targeting Small Molecules
PFE sits 21% above its 52-week low of $23.62.
Summary
Pfizer has entered a research collaboration and license agreement with Enodia Therapeutics to develop Sec61-targeting small molecules. Enodia will conduct discovery activities to screen, optimize, and develop Sec61 inhibitor candidates against multiple collaboration targets, while Pfizer takes on all clinical, manufacturing, regulatory, and commercial responsibilities. The deal carries a total potential value exceeding $500 million, including upfront payments, milestones, and royalties. This expands Pfizer's early-stage pipeline in a novel mechanism and follows a series of recent pipeline advances, including the FDA approval of TUKYSA and positive Phase 2 data for tilrekimig. The collaboration adds a new platform without immediate revenue impact, but signals continued investment in innovative modalities.
At the time of this announcement, PFE was trading at $28.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $161.9B. The 52-week trading range was $23.62 to $29.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.